Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis

British Medical Journal

Volumn 326, Issue 7404, 2003, Pages 1423-1427

  Law, M R ^a   Wald, N J ^a   Rudnicka, A R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; HEPATITIS; HUMAN; ISCHEMIC HEART DISEASE; LIVER FAILURE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHABDOMYOLYSIS; STROKE; THROMBOEMBOLISM; VASCULAR DISEASE;

CEREBROVASCULAR ACCIDENT; CHOLESTEROL, LDL; COHORT STUDIES; DOUBLE-BLIND METHOD; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL ISCHEMIA; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0037490080     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. JAMA 1999;282:2340-6.
2. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:1-5.
3. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Impact on statin trials. Circulation 1998;97:946-52.
4. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.
5. Crouse JR, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998;138:11-24.
6. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. A meta-analysis of randomised, placebo controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-50.
7. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA 1997;278:313-21.
8. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. Ann Intern Med 1998;128:89-95.
9. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995;346:1647-53.
10. Law MR, Wald NH, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994;308:363-6.
11. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308:373-9.
12. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke 1997;28:491-9.
13. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-40.
14. Food and Drug Administration, Center for Drug Evaluation and Research. Statins and hepatotoxicity. www.fda.gov/ohrms/dockets/ac/00/backgrd/3622b2b_safety_review.pdf (accessed 8 Apr 2003).